Blood was obtained on 414 occasions from 106 children with acute lymphocytic leukemia (ALL) or solid tumors. Resting and stimulated hexose monophosphate shunt (HMPS) activity and unstimulated and stimulated nitroblue tetrazolium (NBT) dye reduction were assessed on each sample. The values obtained were compared to similar determinations made on blood obtained from 178 healthy children. Resting HMPS activity of all patients with malignant diseases was significantly ( p < 0.01) greater, and ability to stimulate HMPS activity significantly ( p < 0.01) less than that noted in healthy control patients. Unstimulated NBT dye reduction of leukocytes obtained from patients with malignant disorders was significantly ( p < 0.01) less than that observed in nealthy control children. No significant differences were noted in HMPS activity or NBT dye reduction in patients with ALL, rhabdomyosarcoma, or other solid tumors who had bacterial infection when compared to uninfected patients, or when patients were categorized according to the type of chemotherapy provided. HMPS activity and NBT dye reduction of patients with ALL prior to treatment, in remission, and during episodes of relapse did not differ from each other. Thus, a functional impairment in leukocyte function was noted in patients with ALL even when their peripheral blood and bone marrow cells exhibited normal morphology.
CUWC~ 35~1365-1371, 1975.
NFECTION IS A MAJOR CAUSE OF MORTALITY I and morbidity in patients with leukemia or solid tumors. 13.'8~29 T h e basic neoplastic disease, as well as the chemotherapy or radiation provided, affect the ability of the host to resist or recover from acquired infectious diseases. Patients with leukemia and other neoplasms